series-b
Stage
2018
Founded
3
Investors
About
NMD Pharma discovers and develops novel small molecule therapeutics targeting skeletal muscle ion channels to treat neuromuscular diseases such as myasthenia gravis, spinal muscular atrophy, Charcot-Marie-Tooth disease, and sarcopenia.
Explore NMD Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.